Targeting inhibitor of apoptosis proteins (IAPs) for diagnosis and treatment of human diseases

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):81-9. doi: 10.2174/157489206775246539.

Abstract

Since cell death by apoptosis plays a key role in the regulation of tissue homeostasis, any defect in this intrinsic death program may result in tumor formation. "Inhibitor of apoptosis proteins" (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting effector caspases. Aberrant expression and/or function of IAPs have been implied to be involved in the pathogenesis and progression of various human diseases including cancer, autoimmune disorders or neurodegeneration. Recent insights into the regulation of IAPs have provided the basis for various exciting discoveries aimed at modulating expression or dysfunction of IAPs. Thus, targeting IAPs, e.g. by antisense approaches, RNA interference or small molecules, may proof to be a novel strategy for the diagnosis and treatment of human diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis / physiology*
  • Humans
  • Inhibitor of Apoptosis Proteins / antagonists & inhibitors
  • Inhibitor of Apoptosis Proteins / genetics
  • Inhibitor of Apoptosis Proteins / physiology*
  • Oligonucleotides, Antisense / pharmacology
  • Patents as Topic
  • RNA, Small Interfering / pharmacology
  • Signal Transduction / physiology

Substances

  • Inhibitor of Apoptosis Proteins
  • Oligonucleotides, Antisense
  • RNA, Small Interfering